R. Herbst

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R Herbst, R S Herbst, R. Herbst, Ronald Herbst
Publication record
175 papers · 9,637 citations · H-index 49

PAPERS

Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies
20235 citationsauthor #18
Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction
202226 citationsauthor #16
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
202131 citationsauthor #19
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
202129 citationsauthor #17
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown.
202136 citationsauthor #17
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1
202115 citationsauthor #12
Retraction Note: Microglia-dependent synapse loss in type I interferon-mediated lupus
20203 citationsauthor #10
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
2020143 citationsauthor #30
Immune Complex–Driven Generation of Human Macrophages with Anti-Inflammatory and Growth-Promoting Activity
202010 citationsauthor #11
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
202015 citationsauthor #13
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
2019157 citationsauthor #17
Abstract 1534: MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen presenting cells and promotes a robust anti-tumor immune response in a B16F10 murine tumor model
20190 citationsauthor #5
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
2019120 citationsauthor #19
Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy
20198 citationsauthor #11
Abstract 573: Mutations found by targeted next generation sequencing is associated with intra-tumor immune profile and may predict response to anti-PD1 therapy in lung adenocarcinoma
20190 citationsauthor #13
Abstract 5017: MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote TH1 transformation of the patient tumor microenvironment
20196 citationsauthor #16
The Immunoscore: Colon Cancer and Beyond
2019311 citationsauthor #4
Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors
201978 citationsauthor #15
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
201989 citationsauthor #20
T follicular helper–like cells contribute to skin fibrosis
201893 citationsauthor #22
Abstract LB-296: Discovery and development of MEDI7247, a novel Pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological and solid cancers
20182 citationsauthor #8
Abstract 151: Phenotypic selection screening reveals Annexin A2 as a pancreatic cancer stem cell target
20180 citationsauthor #11
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
201821 citationsauthor #14
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
2018333 citationsauthor #8
Abstract 3820: Novel PD-1/GITRL bispecific fusion protein delivering concurrent T cell co-stimulation and checkpoint pathway inhibition
20181 citationsauthor #6
Amendment history : Erratum ( April 2018 ) Host expression of PD-L 1 determines efficacy of PD-L 1 pathway blockade – mediated tumor regression
2018198 citationsauthor #8
Abstract 567: The lysosomal transporter SLC46A3 is a potential predictive biomarker for antibody-drug conjugates bearing the non-cleavable warheads SG3376 and DM1
20180 citationsauthor #9
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
201833 citationsauthor #30
Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
201853 citationsauthor #18
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
2018974 citationsauthor #27
Abstract 3765: An anti-CD137 antibody can show greater efficacy in syngeneic mouse tumor models when combined with other immuno-oncology (IO) therapies
20180 citationsauthor #10
Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potentin vivoactivity across a spectrum of hematological malignancies
20185 citationsauthor #6
CD19-positive antibody-secreting cells provide immune memory.
201824 citationsauthor #13
Characterisation of innate lymphoid cell populations at different sites in mice with defective T cell immunity
201843 citationsauthor #4
Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers
20188 citationsauthor #13
Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI‐551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease
201833 citationsauthor #10
Impaired Tumor‐Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD‐1 Blockade
201887 citationsauthor #21
Abstract 1676: Involvement of B cells in the efficacy of anti-PD-L1 antibodies: Suppression of B cells by cancer stem cells
20180 citationsauthor #5
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
201835 citationsauthor #33
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
201812 citationsauthor #22
Abstract 1758: Intratumoral IL-12 mRNA promotes cytotoxic T cell-dependent anti-tumor immunity and enhances responses to PD-L1 blockade in pre-clinical models
20180 citationsauthor #15
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
2018276 citationsauthor #16
Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
20182 citationsauthor #12
Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells
201810 citationsauthor #21
Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
20180 citationsauthor #12
SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
201865 citationsauthor #16
Abstract 759: Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
20180 citationsauthor #18
Abstract LB-298: MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors
20185 citationsauthor #8
Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models
20181 citationsauthor #19
Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency
201739 citationsauthor #12
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
201734 citationsauthor #29
Abstract 76: Synthetic lethal targeting ofBRCAmutant tumors with antibody linked pyrrolobenzodiazepine dimers
20173 citationsauthor #8
IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression
2017109 citationsauthor #3
Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors
20171 citationsauthor #8
Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma
201719 citationsauthor #17
Molecular‐based diagnosis of multiple sclerosis and its progressive stage
201746 citationsauthor #10
Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses
201788 citationsauthor #9
Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring.
201710 citationsauthor #14
Microglia-dependent synapse loss in type I interferon-mediated lupus
2017172 citationsauthor #10
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
201761 citationsauthor #6
CD47 limits antibody dependent phagocytosis against non‐malignant B cells
201710 citationsauthor #5
Abstract 2064: Tumor cells treated with a PBD-based antibody-drug conjugate targeting 5T4 develop acquired resistance due to 5T4 down-regulation and response to alternate therapeutics
20171 citationsauthor #13
Abstract 4779: Targeting the CCL20-CCR6 axis as a novel opportunity to stimulataneously modulate cancer stem cells and the tumor-immune infiltrate by a dual anti-cancer mechanism
20176 citationsauthor #6
Autoreactive CD19+CD20− Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis
201646 citationsauthor #8
Prophylactic and therapeutic neutralization of IL-21 bioactivity protects mice from lethality induced by human T cells in a xenogeneic mouse model of graft vs host disease
20160 citationsauthor #4
Abstract CT102: Clinical cancer stem cell targeting in multiple myeloma: an early phase trial of the anti-CD19 monoclonal antibody Medi-551 in combination with lenalidomide and dexamethasone
20160 citationsauthor #9
THU0246 Role of IGE in The Pathogenesis of Tubulointerstitial Inflammation in Human Lupus Nephritis
20160 citationsauthor #3
Autoimmune manifestations in aged mice arise from early-life immune dysregulation
201649 citationsauthor #18
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
2016180 citationsauthor #30
Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice
201626 citationsauthor #6
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
201692 citationsauthor #4
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
201620 citationsauthor #353
Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1
201631 citationsauthor #11
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
201630 citationsauthor #14
Abstract 1475: Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist
20161 citationsauthor #10
Targeting CD73 in the tumor microenvironment with MEDI9447
2016245 citationsauthor #16
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.
201615 citationsauthor #7
Role of BAFF in pulmonary autoantibody responses induced by chronic cigarette smoke exposure in mice
201624 citationsauthor #11
I-07 Ifnar signalling promotes microglia dysfunction in SLE
20160 citationsauthor #6
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
201669 citationsauthor #15
HER2 drives Mucin-like 1 to control proliferation in breast cancer cells
201635 citationsauthor #5
SAT0375 ICOS-ICOSL Modulates Tertiary Lymphoid Organ Formation, Regulating the Lymphotoxin Pathway in an Animal Model of SjÖgren's Syndrome
20150 citationsauthor #6
ICOS is required for the generation of both central and effector CD4+ memory T‐cell populations following acute bacterial infection
201519 citationsauthor #3
MEDI‐551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19
201527 citationsauthor #7
ICOS-ICOSL interaction regulates Lymphotoxin alpha expression and maturation of lymphoid-like stromal cells during inflammation
20150 citationsauthor #5
A2.20 ICOS-ICOSL interaction regulates lymphotoxin alpha expression and maturation of lymphoid-like stromal cells during inflammation
20150 citationsauthor #8
Residual EAE severity following B cell depletion is due to treatment-resistant plasma cells (THER7P.953)
20150 citationsauthor #9
Abstract 4954: Serine/arginine splicing factor 1 (SRSF1) mediates DNA repair and chemo-sensitivity and drives growth in small cell lung cancer
20150 citationsauthor #15
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells
201549 citationsauthor #11
Self-reactive IgE exacerbates interferon responses associated with autoimmunity
2015151 citationsauthor #13
Role of B cell activating factor (BAFF) in Chronic Obstructive Pulmonary Disease
20152 citationsauthor #10
Abstract 2032: Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer
20150 citationsauthor #21
Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease.
2015106 citationsauthor #10
S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo
2015117 citationsauthor #17
Abstract 1538: Levels and enzyme activity of CD73 in primary samples from cancer patients
201513 citationsauthor #10
MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis
2015128 citationsauthor #18
Abstract 4364: Characterization of mucin-like 1 (MUCL1) in breast cancer and its novel role as a potent activator of cell proliferation
20151 citationsauthor #5
CD19 and CD32b Differentially Regulate Human B Cell Responsiveness
201455 citationsauthor #9
This information is current as Human B Cell Responsiveness CD 19 and CD 32 b Differentially Regulate
20140 citationsauthor #2
Germinal Center B Cell Depletion Diminishes CD4+ Follicular T Helper Cells in Autoimmune Mice
201430 citationsauthor #10

TIMELINE

1990 15 citations

1991 54 citations

1992 34 citations

1993 44 citations

1995 77 citations

1996 325 citations

1997 3 citations

1998 31 citations

2000 270 citations

2002 132 citations

2003 44 citations

2004 9 citations

2006 52 citations

2007 30 citations

2008 5 citations

2009 332 citations

2010 1,586 citations

2011 163 citations

2012 151 citations

2013 349 citations

2014 468 citations

2015 613 citations

2016 863 citations

2017 599 citations

2018 2,314 citations

2019 769 citations

2020 171 citations

2021 111 citations

2022 26 citations

2023 5 citations

R. Herbst

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT